MUSTANG BIO, INC. (MBIO): restructuring charge — Mustang Bio cuts workforce by 81% amid CFIUS uncertainty and facility sale to uBriGene

MUSTANG BIO, INC.

Board approved ~81% workforce reduction to reduce costs and preserve capital due to fundraising environment and CFIUS review of facility sale.
Workforce reduction expected substantially complete in Q2 2024; expects ~$0.2M in one-time termination cash expenditures.
Company continues to evaluate all strategic and other alternatives related to the business.
Sale of leasehold interest and assets to uBriGene (Chinese CDMO) pending CFIUS review; terms not disclosed.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

MUSTANG BIO, INC. announced a restructuring with charges of approximately $0.2 million (approximately 81% of its employee base).

Type: restructuring
Charge: approximately $0.2 million
Headcount: approximately 81% of its employee base

Exact text from the filing

to be substantially completed in the second quarter of 2024. As a result of these actions, Mustang expects to incur personnel-related restructuring charges of approximately $0.2 million in connection with one-time employee termination cash expenditures, which are expected to be incurred in the second quarter of 2024. Mustang may also incur other charges or cash

View on SEC.gov

Browse all restructurings & charges →

MUSTANG BIO, INC. filing history →

Source: SEC EDGAR

accession 0001558370-24-005022

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.